With the recent announcement that 3M is spinning off its Health Care division, SmartTRAK looks back at the evolution of 3M Health Care, its businesses today, the entry into Advanced Wound Care (AWC) and potential new opportunities for the new Health Care business.

3M, a large, diversified company with annual sales of $35.4B in 2021 announced earlier this year plans to spin-off its Health Care business into a new public company. Today, 3M markets thousands of products through four business groups: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. Post-spin-off, 3M will continue as a leading global material science innovator, while the new stand-alone business will seek to become a global diversified healthcare company focused on wound care, healthcare IT, oral care and biopharma filtration.


Among the many topics covered in this fascinating article are:

In an interview with SmartTRAK, Parachute Health CEO David Gelbard discusses the Company and its novel, online DME ordering system for medical devices and supplies that benefit the patient, provider and supplier eliminating the challenges of the ancient fax world.

Parachute Health has implemented a novel, online ordering system that is used for a variety of DME supplies including mobility, sleep therapy and respiratory aids, along with diabetes, wound care, ostomy and urology incontinence supplies. The system benefits the patient, provider and supplier by creating a win, win, win for all and eliminates the challenges of the back-and-forth approval process associated with faxing requests.

In an interview with SmartTRAK, Parachute Health’s CEO, David Gelbard said he founded the Company because his father did not receive an important DME supply after leaving the hospital, causing him to fall at home and requiring additional care. David’s vision for the Company is to establish the infrastructure for DME supplies such that its ease-of-use replicates that of ordering shoes on Amazon or swiping your credit card at a local coffee store. Today, the Company operates across the US at 40,000 different sites of care, from hospitals, nursing homes and doctor’s offices to home health and hospice agencies, and has a network of over 100,000 physicians and prescribers—a number that is rapidly growing. To find out more about the Company and its operation, click on the following video to listen to SmartTRAK’s interview with David Gelbard, recorded via Uberconference (23:35 min). A link to the complete transcript of the interview is also provided below.

A big boost in Q2 with double-digit gains in all segments.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q221 US Infection Prevention - Vascular Access Adjunct Products Market Recap* are:

Advanced Wound Care saw a strong recovery against a weak comparator.

For Q221, according to SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up, with all segments showing increases,

The US Wound Biologics market, comprising the vast majority of the global biologics market, includes the very competitive skin substitute or CTP (Cellular and/or Tissue-Based Products) market, the Topical Drug/Delivery category and Collagen Dressings. For Q221, the US market was up significantly, with CTPs accounting for the largest share, driven by Organogensis' substantial YoY gains. 

Among the many topics covered in detail in our comprehensive Q221 Advanced Wound Care Market Recap* are:

Changing market dynamics over the past ten years has not held back the robust Skin Substitute/CTP market.

As SmartTRAK celebrates its 10-year anniversary covering AWC and the Biologics area, we look back at the market drivers, products and players to see how the US Skin Substitute market has changed over the last decade. We also look ahead to see what is in store for the Skin Substitute market, which is projected to reach $1.64B in 2025E.

The following is a preview of our Wound Biologics market retrospective. The full article, available on SmartTRAK, features our industry experts discussing and analyzing these changes and trends in detail.

A return to positive growth for the quarter, but gains lag behind pre-COVID-19 levels.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q121 US Infection Prevention - Vascular Access (VA) Adjunct Products Market Recap* are:

Advanced Wound Care begins to stabilize as in-person visits increase and elective procedures rebound.

For Q121, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +6.2%, boosted by a strong performance in Biologics, with 3M maintaining the number one position in the AWC space.

Among the many topics covered in detail in our comprehensive Q121 AWC Market Recap* are:

The Symposium on Advanced Wound Care, SAWC, the official meeting of the Wound Healing Society, was held virtually May 10-14 and SmartTRAK attended.

Following is a sampling of some of the takeaways from the meeting that were gathered and curated by our expert analysts and sent out to subscribers in our Daily Updates.

A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.

For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.

Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are:

Anticipated growth for Q4 was weakened by a resurgence of COVID-19 and was not enough to sustain growth with FY20 ending at -3.3% YoY decline.

For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up  +1.2% YoY.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are: